Healthcare is one of the few sectors where regulatory barriers are not just obstacles — they are assets. An MHRA medical device approval, an FDA 510(k) clearance, or a CQC registration represents years of investment and creates a moat that no amount of capital can shortcut.
Combined with clinical data that compounds with every patient interaction and technology protected by patents and trade secrets, healthcare companies build intangible asset portfolios of exceptional depth and defensibility.
Healthcare intangible assets are distinguished by their regulatory origins and data intensity. The barriers to entry created by regulatory approvals, the competitive moats built by clinical data accumulation, and the innovation protected by medical IP create one of the most defensible intangible asset profiles of any sector.
Regulatory approvals in healthcare are intangible assets with quantifiable replacement costs and strategic value that often exceeds those costs.
| Approval Type | Jurisdiction | Typical Timeline | Replacement Cost |
|---|---|---|---|
| MHRA Medical Device (Class IIa+) | UK | 12-24 months | £300K-1.5M |
| CE Marking (MDR) | EU | 18-36 months | £500K-3M |
| FDA 510(k) | US | 6-18 months | £200K-1M |
| FDA PMA | US | 24-48 months | £2M-10M |
| CQC Registration | UK | 3-12 months | £50K-200K |
| NICE Technology Appraisal | UK | 12-24 months | £500K-2M |
The cost approach is the standard valuation method for regulatory approvals. Replacement cost includes direct costs (clinical studies, regulatory consultants, submission fees), opportunity costs (time to market), and the probability-adjusted cost of failure (not all submissions succeed).
A healthtech startup developed an AI-powered diagnostic tool and obtained MHRA Class IIa approval after 18 months of clinical validation. The total cost was £800K (clinical studies, regulatory consultants, quality management systems). But the replacement cost to a competitor would be higher — at least £1.2M — because the startup's team had learned from two rejected submissions before succeeding. This learning is embedded in the final approval and cannot be shortcut.
Healthcare data assets are unique in their sensitivity, regulatory complexity, and strategic value. Clinical datasets — patient outcomes, diagnostic results, treatment efficacy, adverse event records — compound in value as they grow.
Real-world evidence (RWE) — outcomes data collected from actual clinical use, as opposed to controlled trial environments. RWE is increasingly required by regulators and payers, and proprietary RWE datasets are difficult to replicate.
Training data for clinical AI — labelled datasets used to train diagnostic algorithms, risk prediction models, and treatment recommendation systems. The labelling process (typically requiring specialist clinician review) is expensive and time-consuming, making these datasets highly valuable intangible assets.
Patient registries — structured databases tracking patient populations over time. Registries provide longitudinal insights that cross-sectional data cannot, and their value increases with duration and completeness.
Healthcare data valuation must account for regulatory constraints. GDPR, UK Data Protection Act 2018, and sector-specific regulations (such as the Common Law Duty of Confidentiality) limit how data can be used and shared. These constraints do not eliminate value — they create scarcity that can increase it. A properly consented, GDPR-compliant dataset is more valuable than a larger unconsented one because it can be commercially exploited.
Healthcare technology IP spans software, devices, and methods — each with different protection strategies and valuation characteristics.
Clinical AI presents particular valuation challenges. The value of a diagnostic AI model depends on the training data (a separate data asset), the algorithm architecture (technology capital), the regulatory approval (a separate regulatory asset), and the clinical validation evidence (a component of both the data and regulatory assets).
In a PPA, these components may be separately identified — or the AI system may be valued as a single technology asset with contributory charges for the data and regulatory components.
Customer relationships in healthcare vary significantly by segment.
| Segment | Customer Type | Relationship Character | Switching Costs |
|---|---|---|---|
| MedTech / Devices | NHS trusts, hospital groups | Procurement-driven, contract-based | High (clinical workflow integration) |
| Health Software | Clinicians, health systems | Licence or SaaS-based | Very high (training, data migration) |
| Digital Health | Patients / consumers | Subscription or usage-based | Low-moderate |
| Clinical Services | Commissioners, insurers | Framework agreements | Moderate-high |
Healthcare switching costs are typically higher than other sectors because clinical workflow integration, staff training, and data migration create friction that discourages change. These high switching costs make healthcare customer relationships particularly valuable intangible assets.
Regulatory approvals are not sunk costs — they are appreciating assets that create barriers to entry. Each approval obtained adds to the intangible asset base and strengthens the competitive moat.
Capture, structure, and properly consent clinical data from the earliest possible stage. The compounding value of well-structured data assets makes early investment disproportionately valuable.
Combine patents (for innovations that benefit from public disclosure and legal exclusion) with trade secrets (for processes and data that benefit from secrecy). Multiple protection layers create deeper moats.
Healthcare intangible assets are among the most valuable and defensible in any sector. The combination of regulatory barriers, data compounding, and technology IP creates competitive moats that persist for years or decades. Companies that recognise and manage these assets command premium valuations.
The Opagio Intangibles Questionnaire evaluates intangible assets across regulatory, technology, data, and customer relationship categories. The Intangible Asset Valuator supports cost approach, Relief from Royalty, and MPEEM calculations for healthcare-specific assets.
Ivan Gowan is the Founder and CEO of Opagio. With 25 years in financial technology and experience in regulated industries — including building platforms that process sensitive financial data under FCA oversight — he brings practical understanding of how regulatory approvals and data assets create defensible intangible value. Meet the team.
Healthcare and MedTech companies invest billions in clinical evidence, regulatory approvals, and proprietary health data — assets that represent formidable barriers to competition and durable sources of revenue. Yet these assets remain largely invisible to the lending market. Here is how structured intangible collateral can transform healthcare financing.
Read more →
Pharmaceutical companies derive the vast majority of their value from intangible assets — drug patents, clinical trial data, regulatory approvals, and the pipeline of compounds in development. Valuing these assets requires specialised methods that account for the unique risk profile and regulatory pathway of drug development.
Read more →Get the latest insights on intangible asset growth and productivity delivered to your inbox.
Book a free consultation to see how Opagio Intangibles can help your business.